Investment Management of Virginia’s Ligand Pharmaceuticals LGND Stock Holding History

Investment Management of Virginia’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,964	Closed	-$2.47M	–	181
2022 Q3	$2.47M	Buy	45,964 +1,112	+2%	+$65.4K	0.53%	64
2022 Q2	$2.5M	Sell	44,852 -14,853	-25%	-$843K	0.51%	69
2022 Q1	$4.19M	Sell	59,705 -12,036	-17%	-$873K	0.74%	51
2021 Q4	$6.91M	Sell	71,741 -639	-0.9%	-$59K	1.11%	24
2021 Q3	$6.29M	Buy	72,380 +5,695	+9%	+$440K	1.21%	23
2021 Q2	$5.46M	Sell	66,685 -3,892	-6%	-$324K	1.05%	27
2021 Q1	$6.71M	Buy	70,577 +16,726	+31%	+$1.58M	1.35%	18
2020 Q4	$3.34M	Buy	53,851 +24,396	+83%	+$1.39M	0.73%	45
2020 Q3	$1.75M	Buy	+29,455	New	+$2.01M	0.44%	69

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Investment Management of Virginia's LGND Position: Q4 2022 in Review

Investment Management of Virginia sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 45,964 shares — an estimated $2.47M sold.

Investment Management of Virginia first reported a position in LGND in Q3 2020 and held it in 9 quarters. The position peaked at $6.91M in Q4 2021. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Investment Management of Virginia reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Investment Management of Virginia sold 45,964 Ligand Pharmaceuticals shares in Q4 2022, an estimated $2.47M.
Investment Management of Virginia first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 9 quarters.
Investment Management of Virginia's Ligand Pharmaceuticals position peaked at $6.91M in Q4 2021.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Investment Management of Virginia's 13F filing for Q4 2022, filed 23 Jan 2023.